




# NEOADJUVANT THERAPY



<http://www.ohsu.edu/research/rda/so/knight.php>

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

## BREAST CANCER



KNIGHT  
CANCER  
Institute

# ADJUVANT THERAPY

HR-positive  
HER2-negative

**IRB#22395**

**DARE:** DNA-Guided  
Second Line Adjuvant  
Therapy For High  
Residual Risk, Stage II-III

HER2-positive

*No trial currently  
available*

Triple  
Negative

**IRB#17461**

**SWOG S1418:** Pembrolizumab  
as Adjuvant Therapy for Triple  
Receptor-Negative Breast  
Cancer

**IRB#22388**

**Ipi/Nivo/Cryo:** Peri-Operative  
Ipilimumab+Nivolumab and  
Cryoablation Versus Standard  
Care

**Key**


- Open for Enrollment
- In Development
- Enrollment on Hold

<http://www.ohsu.edu/research/rda/so/knight.php>

BREAST CANCER



# METASTATIC THERAPY




In Development

Enrollment on Hold

<http://www.ohsu.edu/research/rda/so/knight.php>



# METASTATIC THERAPY




**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

<http://www.ohsu.edu/research/rda/so/knight.php>

## BREAST CANCER

# METASTATIC THERAPY



### Key

- Open for Enrollment
- In Development
- Enrollment on Hold

<http://www.ohsu.edu/research/rda/so/knight.php>

## BREAST CANCER



## CROSS-DISEASE TRIALS

**IRB#15588**

(SMART-PRIME)

- Heavily Pre-treated
- HR+HER2-; HER2+; TNBC

**IRB#20679**

(SMART-ACT)

- HR+HER2-; HER2+; TNBC
- Pre-screen (molecular target)

**IRB#19904**

NEO-RAY (Nuc Med)

- Heavily Pre-treated
- Pre-screen required

**IRB# 19992**

EAY131 (MATCH)

- Pre-screen (molecular target)

**IRB#18084**

S1609 (DART)

- Pre-screen (rare molecular target)

**IRB#19489**

(Lutathera IIT)

- Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera

**IRB#16676**

BLU-667 (Phase 1)

- Advanced solid tumor with oncogenic RET fusion (expected to close soon)

**IRB#18164**

Loxo RET (Phase 1)

- RET fusion-positive

<http://www.ohsu.edu/research/rda/so/knight.php>

 Enrollment on Hold

## BREAST CANCER

## Breast Cancer



# CROSS-DISEASE TRIALS

## Continued

**IRB#21349**

MORAB-202 (Phase 1)

- **TNBC:** Previously treated (cytotoxic or targeted anticancer agents) in the metastatic setting.

**IRB#21766**

GEN001 (Phase 1)

- Patients must have progressed on at least two lines of approved therapy for their histological subtype

**IRB# 21508**

ORIC-101 (Phase 1)

- **TNBC** with no alternative effective standard therapy

**IRB#21548**

AMG 650 (Phase 1)

- **TNBC** relapsed/refractory to at least one line of systemic chemotherapy in the metastatic setting or intolerant of existing therapy(ies).

**IRB#21819**

ASTX029 (Phase 1)

- **Phase 1B:** documented activating gene mutations in BRAF (BRAF V600 mutation or activating atypical non-V600 aberrations), KRAS, NRAS, or HRAS

<sup>1</sup> To inquire about Phase 1 trial open slots please contact [stadnik@ohsu.edu](mailto:stadnik@ohsu.edu).



<http://www.ohsu.edu/research/rda/so/knight.php>